FILGRASTIM
No Evidence of Disease
University of Washingtonprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the No Evidence of Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxybutynin Academic and Community Cancer Research United | Phase 3 | BB |
FLUTICASONE University of Washington | Phase 1 | CC |
Sargramostim University of Washington | Phase 1 | CC |
Pumvc3-Igfbp2-Her2-Igf1R Plasmid Dna Vaccine University of Washington | Phase 1 | CC |
Cediranib National Cancer Institute (NCI) | Phase 1 | CC |
METHYLSELENOCYSTEINE, L- National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →